Avid Bioservices Inc (CDMO)

[jakedogman1]

read the halo cc transcript and the latest halo investor presentation

https://s21.q4cdn.com/250105458/files/doc_presentations/2019/HALO-010919-JPM_FINALv2.pdf

cdmo produces for roche/halo .... expansion/capital raise around the corner?? .... someone wants your shares... all imo

and the last cdmo cc transcripts (excerpt below)

Equally as important as engaging new customers is the increasing strength of our relationships with our existing customers. During Q2, we gained increased visibility into forecast for several of our larger ongoing programs. Customer concerns related to confidentiality prevent us from sharing these specific projections based on this information at this time, but we believe demand from these customers will positively impact revenue, margins, and capacity in the coming quarters. Unsurprisingly, given the history of the relationship between our two companies and its importance, we are frequently asked about our business with Halozyme Therapeutics and the outlook for continued commercial manufacturer of enzyme products used in their enhanced platform by their partner companies such as Roche. Our relationship with Halozyme remains strong and we were able to review, both technical & commercial progress with our colleagues there at a recent business review meeting. Halozyme’s booked sales of recombinant human hyaluronidase enzymes and enhanced drug products have recently increased, and this trend is expected to continue into 2019, as Halozyme partners advance their clinical programs and begin preparing for commercialization.